Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Ultragenyx Pharmaceutical's Rivunatpagene Miziparvovec?
Rivunatpagene Miziparvovec is a gene therapy commercialized by Ultragenyx Pharmaceutical, with a leading Phase III program in Wilson Disease. According...
Data Insights
Risk adjusted net present value: What is the current valuation of Ultragenyx Pharmaceutical's Rivunatpagene Miziparvovec?
Rivunatpagene Miziparvovec is a gene therapy commercialized by Ultragenyx Pharmaceutical, with a leading Phase III program in Wilson Disease. According...